Dimension vista 1500

Blood samples were collected from the antecubital vein in all enrolled patients. The collected serum samples were stored at -20 C° until instrumental analysis.
Serum CysC was measured by a particle-enhanced immuno-nephelometric assay (N Latex Cystatin C, BN ProSpec nephelometer, Siemens Healthcare Diagnostics).
sCrea and hs-CRP measurements were performed by an automated method using Dimension VISTA 1500 (Siemens Healthcare Diagnostics, Milano, Italy).
Fibrinogen was quantified by phototurbimetric method (Ca 7000 Sysmex, Japan).

Estimates of GFR were calculated on the basis of serum creatinine, cystatin C and creatinine-cystatin C, according to the equations of the Chronic Kidney Disease Epidemiology Collaboration^{16 (link),17 (link)}. Venous blood was drawn from all study participants at the examination appointment and sent to the laboratory department of Augsburg Central Hospital within 2 to 4 h. Serum creatinine concentration were analyzed using an enzymatic colorimetric method (Dimension Vista 1500, Siemens Healthcare Diagnostics, Eschborn, Germany, or Cobas c702, Roche Diagnostics GmbH, Mannheim, Germany). Cystatin C levels were assessed using a nephelometric immunoassay (normal range 0.50–0.96 mg/L, Roche Diagnostics GmbH, Mannheim, Germany)^{18 (link),19 (link)}. Urinary albumin concentration was measured using an immunoturbidimetric assay (Tina-quant_Albumin in Urine, Boehringer Mannheim, Germany) from a single urine sample stored at − 80 °C^{19 (link)}. eGFR was calculated on the basis of the Chronic Kidney Disease Epidemiology Collaboration equation, which is based on both serum creatinine and cystatin C^{16 (link)}.

CRP levels were measured with the Dimension Vista 1500 (Siemens Healthcare diagnostics). WBC counts were determined on a Sysmex XE-2100 hematology analyzer (Sysmex Corporation, Kobe, Japan). Neutrophil-Lymphocyte Count Ratio (NLCR) was determined by dividing the absolute neutrophil count by the absolute lymphocyte count. To additionally determine suPAR and PCT levels, serum was thawed on ice. suPAR levels were determined by using the suPARnostic ELISA kit (Virogates, Copenhagen, Denmark) according to the manufacturer’s instructions, and PCT levels were measured using the Cobas E411 (Roche Diagnostics).

Blood samples were collected between January and April 2022. Fasting and morning samples were performed to measure iFGF23 levels in sterile EDTA vacutainers, centrifuged at 3000 × g, 10 min, 4° C. Plasma was removed and aliquoted into polypropylene tubes for storage at -80° C pending testing. Before storage the samples were evaluated for interference from hemolysis (hemoglobin> 1,000 mg/dL), jaundice (conjugated and unconjugated bilirubin greater than 20 mg/dL) and chylosity (triglyceride concentrations> 3,000 mg/dL) the HIL method [Dimension VISTA 1500 instrumentation (Siemens, Munich, Germany)]. The sample was thawed at room temperature prior to analysis.

The list of analytes measured for the selection of subjects; the reference intervals are differentiated by age and sex are in Table 1. Dosage of 25 (OH) Vitamin D was performed with chemiluminescence assay using the TGSTA Technogenetics instrumentation (Technogenetics, Milano-Italy). Serum calcium, phosphorus, iron, glucose, albuminemia, was carried out using the spectrophotometric method; bichromatic endpoint technique (polychromatic albumin andpoint); serum sodium, potassium, was carried out using potenziomatric method, creatinine (coupled enzymatic) liver enzyme (AST, ALT) was carried out by enzyme method (bichromatic kinetic technique); TSH, FreeT4, ferritin was carried out by chemiluminescente methodica (LOCI) Transferring (immunoenzymatica) and PCR CRP was carried out by nephelometric method. These analytes were assayed on These following analytes were assayed on Dimension VISTA 1500 instrumentation (Siemens, Munich, Germany). count The samples were collected in tubes with EDTAK3 anticoagulant for blood count and analyzed on ADVIA 2120i hematology analyzer.
Renal function was assessed based on creatinine levels and estimated glomerular filtration rate (eGFR) with Schwartz equation [k × height (cm)/serum creatinine], with different k values for age and sex (k = 0.450, 0.55, 0.7 for infants aged less than 12 months, <12 years and children ≥13 years, respectively).

Serial blood samples were taken from all ECPR patients directly upon arrival at the emergency department. The first sample was collected from the venous line of the ECMO system, and subsequent samples were collected arterially according to our department’s standard blood sampling protocol for ECPR patients. Serum blood samples were collected at 1, 4, 12, 24, 48, 72 and 96 h after VA ECMO implantation. The fully-blinded serum samples were analyzed at the Department of Clinical Chemistry, University Hospital Regensburg. To obtain measurements of S100, IL6 and NSE, a quantitative automated immunoassay (Cobas e411, Roche Diagnostics, Indianapolis, United states) was used. Lactate was measured using quantitative automated photometry (Siemens Dimension Vista 1500, Newark, Germany), fibrinogen was measured using quantitative automated coagulometry (Siemens BCS XP, Newark, Germany) and platelet count was analyzed using flow cytometry (Sysmex XE-5000, Kobe, Japan). All laboratory data were extracted from the clinic’s database system and the ECMO database. Prior to ECPR, no patient had known comorbidities associated with increased NSE or S100 values.